Latest Content

FDA Approves Cabometyx-Opdivo For Metastatic RCC Treatment

January 22nd 2021, 7:48pm

By Conor Killmurray

Article

After a fast-track designation, the Food and Drug Administration approved the combination of Cabometyx and Opdivo in the firstline setting for patients with advanced or metastatic renal cell carcinoma.

Novel Therapy Granted Priority Review By FDA for Treatment of Anal Cancer Subset

January 22nd 2021, 7:00pm

By Ryan McDonald

Article

The priority review will focus on retifanlimab for the treatment of certain adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who did not tolerate platinum-based chemotherapy. Currently, according to Incyte, there are no approved treatments for this patient population.

COVID-19 'Retired' Me, But Now I Can Reach For My Life Goals

January 22nd 2021, 5:00pm

By Marissa Holzer

Article

With a terminal illness of metastatic breast cancer, I qualify for Social Security Disability as the COVID-19 pandemic has retired me, but that isn't stopping me from achieving my life goals.

Friday Frontline: Marine Veteran Has Walked More Than 8,000 Miles to Raise Cancer Awareness and Funds for Strangers Treatments, Researchers Use Cancer Cells From Osteosarcoma Donor for Treatment Breakthrough, And More

January 22nd 2021, 4:00pm

By Conor Killmurray

Article

From a Marine veteran walking 8,500 miles over the last 24 years to raise cancer awareness and funds for treatment to researchers using cancer cells from a deceased osteosarcoma donor to help advance treatment, here’s what’s happening in the cancer landscape this week.

Oral Contraceptives May Reduce Endometrial, Ovarian Cancer Risk Decades After Stopping Use

January 22nd 2021, 2:00pm

By Colleen Moretti

Article

Women who reported using oral contraceptives had a decreased risk of endometrial and ovarian cancer, compared to those who never used the hormone medications. The data also indicated the association extended up to three decades after patients stopped using the contraceptives.

Hydration Performance Drink Aims to Address Fatigue, Dehydration From Cancer Treatments

January 21st 2021, 10:00pm

By Kristie L. Kahl

Article

SWORD Performance Hydration is a natural drink that helps to hydrate and energize individuals, and could even assist with some toxicities that are a result from chemotherapy.

Novel Therapy Shows Promise in Liver Cancer Subset, May Address ‘Urgent Need for New Therapies’

January 21st 2021, 7:00pm

By Ryan McDonald

Article

“Along with a tolerable safety profile and supportive quality of life, these final efficacy results demonstrate the clinical benefit of (Tibsovo) in (previously treated patients with IDH1-mutant cholangiocarcinoma), for which there is an urgent need for new therapies,” said an expert from Massachusetts General Hospital, who presented the data.

Marking An Anniversary Cancer Survivors Never Wanted

January 21st 2021, 5:00pm

By Bill Ramshaw

Article

It's important for cancer survivors to recognize the major milestones and anniversaries in their cancer journey. Even if it's an anniversary they didn't want.

Identifying and Addressing the Barriers to Clinical Trial Access

January 21st 2021, 4:00pm

By Jessica Skarzynski

Podcast

This week on the “CURE® Talks Cancer” podcast, we spoke with Martha Raymond, of The Raymond Foundation, about how providers can ensure patient safety to increase trial enrollment during the COVID-19 pandemic, and what she and her colleagues are doing to provide better trial access to all patients with cancer.

Bavencio Shows No Improvement of Overall Survival for Patients with Gastric Cancers

January 21st 2021, 2:00pm

By Colleen Moretti

Article

For patients with gastric/ gastroesophageal cancer, treatment with Bavencio after chemotherapy shows favorable safety, but no overall survival improvement.

Clinical Trials Can Be Scary – But with Advice From Past Participants, They Don’t Have To Be

January 20th 2021, 10:00pm

By Jessica Skarzynski

Video

Clinical trials may seem scary and challenging for patients with cancer, but in reality, they don’t have to be. Here is how talking to former patients on clinical trials can help.

Real-World Patients May Have More Side Effects to Immunotherapy for Lung Cancer Compared With Clinical Trial Data

January 20th 2021, 7:00pm

By Darlene Dobkowski, MA

Article

Findings from a study focused on patient-reported experiences, found that aching joints, aching muscles and fatigue were more common than initially found in clinical trials.

Appointment Fatigue is a Real Thing And Here’s How to Manage It

January 20th 2021, 5:00pm

By Ron Cooper

Article

Appointment fatigue is a real thing for patients with cancer and even survivors, but there are ways to overcome it.

FDA Grants Priority Review for Opdivo for Several Gastrointestinal Cancers

January 20th 2021, 4:00pm

By Darlene Dobkowski, MA

Article

The priority review will focus on Opdivo with chemotherapy for the treatment several gastrointestinal cancers, which has recently become a rising area in novel treatment development.

Inlyta-Synthetic Hormone Combo Fails to Significantly Improve Survival Outcome in Pancreatic Neuroendocrine Tumors

January 20th 2021, 2:00pm

By Ryan McDonald

Article

The combination of Inlyta (axitinib) and the synthetic hormone octreotide acetate failed to significantly improve progression-free survival, compared to placebo with the synthetic hormone. However, the results indicated the Inlyta-based combination did improve disease response in patients versus the placebo-based combination.